Want to see HK:3869 full AI Analyst Report?
Hospital Corporation of China Ltd (3869) AI Stock Analysis
Hospital Corporation of China Ltd
(HKEX:3869)
The score is held back primarily by balance-sheet leverage and weak technical positioning (price below key moving averages with negative MACD). Financial performance provides partial offset due to the strong 2025 revenue rebound and return to profitability with positive free cash flow, but valuation is unattractive/unclear given the negative P/E and no dividend yield data.
Hospital Corporation of China Ltd (3869) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 464.09M
- Dividend Yield
- ―
- Average Volume (3M)
- 300
- Price to Earnings (P/E)
- -143.6
- Beta (1Y)
- -0.10
- Revenue Growth
- 3.16%
- EPS Growth
- -101.02%
- Country
- Hong Kong
- Employees
- 1,835
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Hospital Corporation of China Ltd Business Overview & Revenue Model
Company Description
Hospital Corporation of China Limited, an investment holding enterprise, primarily focuses on the administration and direct management of hospitals across the People's Republic of China. The company extends specialized management and consulting servi...
How the Company Makes Money
Hospital Corporation of China Ltd primarily generates revenue by providing medical and healthcare services to patients through its operated medical institutions. Key revenue streams typically include fees for outpatient consultations, inpatient servi...
Hospital Corporation of China Ltd Financial Statement Overview
Summary
Operating results improved sharply in 2025 with revenue up 35.3% and a return to profitability (~9.3% net margin) after a 2024 loss, supported by consistently positive free cash flow. However, balance-sheet risk remains a meaningful drag: leverage is still high (debt-to-equity ~2.10x in 2025) and operating cash flow is modest relative to the debt load, limiting near-term self-deleveraging capacity. Profitability also shows year-to-year volatility versus the stronger 2023 margin profile.
Income Statement
66PositiveBalance Sheet
48NeutralCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.47B | 1.47B | 1.44B | 1.43B | 1.14B | 520.29M |
| Gross Profit | 267.62M | 267.62M | 275.82M | 239.36M | 150.88M | 214.23M |
| EBITDA | 183.26M | 183.01M | 243.34M | 283.48M | -464.44M | -401.87M |
| Net Income | 136.42M | 136.42M | -38.63M | 131.38M | -480.95M | -280.71M |
Balance Sheet | ||||||
| Total Assets | 2.58B | 2.58B | 2.58B | 2.50B | 2.44B | 3.12B |
| Cash, Cash Equivalents and Short-Term Investments | 805.00M | 805.00M | 813.08M | 667.89M | 627.61M | 779.97M |
| Total Debt | 1.06B | 1.06B | 1.15B | 1.04B | 1.10B | 1.09B |
| Total Liabilities | 1.86B | 1.86B | 2.01B | 1.91B | 1.99B | 1.99B |
| Stockholders Equity | 502.72M | 502.72M | 337.71M | 379.09M | 255.71M | 797.97M |
Cash Flow | ||||||
| Free Cash Flow | 141.97M | 137.27M | 196.87M | 67.40M | 126.49M | 117.27M |
| Operating Cash Flow | 165.31M | 158.92M | 212.07M | 82.69M | 143.13M | 133.07M |
| Investing Cash Flow | -113.81M | -107.87M | 42.64M | -15.52M | 187.16M | 13.96M |
| Financing Cash Flow | -110.00M | -98.00M | -64.00M | -41.62M | -279.34M | -550.82M |
Hospital Corporation of China Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3869, the sentiment is Negative. The current price of 3.38 is above the 20-day moving average (MA) of 3.38, below the 50-day MA of 3.39, and below the 200-day MA of 3.82, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 0.21 is Positive, neither overbought nor oversold. The STOCH value of -0.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3869.
Hospital Corporation of China Ltd Peers Comparison
Overall Rating
HK:368964Neutral
HK:607862Neutral
HK:990651Neutral- HK:386950Neutral
HK:245343Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:3689 | 64Neutral | HKD 581.85M | 5.27 | 6.35% | 10.92% | -0.27% | 29.73% |
| HK:6078 | 62Neutral | HKD 5.84B | 27.81 | 2.55% | ― | 1.59% | -58.55% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9906 | 51Neutral | HKD 936.00M | 23.35 | 5.59% | ― | ― | ― |
| HK:3869 | 50Neutral | HKD 467.79M | -143.62 | -0.41% | ― | 3.16% | -101.02% |
| HK:2453 | 43Neutral | HKD 489.79M | -2.69 | -8.65% | ― | 47.93% | 65.94% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3869 | Hospital Corporation of China Ltd | 3.38 | -2.61 | -43.49% | |
| HK:9906 | Honliv Healthcare Management Group Co Ltd | 1.56 | -0.05 | -3.11% | |
| HK:3689 | Guangdong Kanghua Healthcare Co., Ltd. Class H | 1.74 | -0.03 | -1.97% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% | |
| HK:6078 | Hygeia Healthcare Holdings Co., Ltd. | 9.51 | -3.88 | -29.01% | |
| HK:2453 | Concord Healthcare Group Co., Ltd. Class H | 0.63 | -1.81 | -74.39% |
Hospital Corporation of China Ltd Corporate Events
Hospital Corporation of China Reshapes Board to Bolster Governance and Compliance
Hospital Corporation of China Limited is a Hong Kong-listed healthcare group that operates and invests in hospital and medical services businesses in China, supported by institutional capital and experienced board members. The company’s governa...
Hospital Corporation of China Updates Board and Committee Structure
Hospital Corporation of China Limited has announced the latest composition of its board of directors, detailing the roles of executive, non-executive and independent non-executive members. The board continues to be chaired by executive director Cao Y...
Hospital Corporation of China Posts Strong Adjusted Profit Despite Flat Revenue
Hospital Corporation of China Limited reported unaudited interim results for the six months ended 30 June 2026, showing relatively stable revenue at RMB732.8 million versus RMB743.0 million a year earlier. General hospital services continued to accou...
Hospital Corporation of China Sets Board Meeting to Review Interim Results and Dividend
Hospital Corporation of China Limited has scheduled a board meeting for 25 August 2026 to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. The board will also consider the possible declaration of a...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026